Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Healius Limited ( (AU:HLS) ) has provided an update.
Healius Limited announced the appointment of Christopher Hall as a director, effective from September 30, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, which could potentially enhance its market position and operational capabilities in the healthcare sector.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, providing medical and diagnostic services. The company focuses on delivering healthcare solutions across various segments, including pathology and imaging services, catering to the needs of patients and healthcare providers.
Average Trading Volume: 4,870,305
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$541M
See more insights into HLS stock on TipRanks’ Stock Analysis page.